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Background: Limited knowledge of the local molecular epidemiology and the paucity of new effective antibiotics
has resulted in an immense challenge in the control and treatment of extensively drug-resistant (XDR) Acinetobacter
baumannii infections in Thailand. Antimicrobial combination regimens may be the only feasible treatment option in
such cases. We sought to characterize the local molecular epidemiology and assess the bactericidal activity of
various antibiotics individually and in combination against XDR A. baumannii in a Thai hospital.
Methods: All XDR A. baumannii isolates from Thammasat University Hospital were collected between October 2010
and May 2011. Susceptibility testing was conducted according to reference broth dilution methods. Pulse-field
gel electrophoresis was used to genotype the isolates. Carbapenemase genes were detected using polymerase chain
reaction. In vitro testing of clinically-relevant concentrations of imipenem, meropenem, doripenem, rifampicin and
tigecycline alone and in combination with polymyxin B was conducted using multiple combination bactericidal testing.
Results: Forty-nine polymyxin B-susceptible XDR A. baumannii isolates were identified. blaOXA-23 and blaOXA-51 genes were
detected in all isolates. Eight clonally related clusters were identified, resulting in the initiation of several infection control
measures. Imipenem, meropenem, doripenem, rifampicin, and tigecycline in combination with PB respectively, exhibited
bactericidal killing in 100%, 100%, 98.0%, 100% and 87.8% isolates respectively at 24 hours.
Conclusion: Molecular epidemiologic analysis can aid the early detection of infection outbreak within the institution,
resulting in the rapid containment of the outbreak. Imipenem/meropenem/rifampicin in combination with polymyxin B
demonstrated consistent bactericidal effect against 49 blaOXA-23-harbouring XDR A. baumannii clinical isolates, suggesting
a role of combination therapy in the treatment of these infections.
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Acinetobacter baumannii (AB) is one of the leading
causes of various nosocomial infections. Its success is
due to its resilient and virulent properties, as well as its
potential to acquire a plethora of drug resistance mecha-
nisms [1]. In Thailand, AB infections represent a key* Correspondence: anapisarn@yahoo.com
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matic increase in carbapenem-resistant AB from 2.1% in
2000 to 46.7% in 2005 [2].
The management of these extensively drug-resistant
(XDR) AB infections is particularly challenging due to
the limited molecular epidemiologic data available. The
drying antibiotic pipeline has also put us at risk of
having no effective treatment options against infections
caused by this bacterium in the near future [3]. This
dearth in new antibiotics has led to the renewed clinical
use of polymyxin antibiotics, the last resort treatmentis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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concerns related to polymyxin monotherapy, the primary
being the emergence of heteroresistance and adaptive
resistance, potentially leading to clinical failure [5-7].
As a consequence of this seemingly futile situation,
combination antibiotic therapies are explored as potential
therapeutic options. Previous in vitro studies investigating
the benefits of combination therapy for the treatment of
XDR AB suggest that effective combinations may be
strain- or clone-specific [8-10]. As limited combination
studies were performed on local Thai isolates [11-14], the
objective of this study was to assess the bactericidal activ-
ity of various antibiotics individually and in combination
against XDR AB, in addition to the characterization of the
molecular epidemiology of XDR AB in Thailand.
Materials and methods
Microorganisms
Forty-nine clinical AB isolates from various sites (body
fluid, blood, pus, sputum and urine) were collected from
Thammasat University Hospital between October 2010
and May 2011. The isolates were identified via a com-
mercial biochemical identification system using colonies
obtained from overnight growth on solid media (API
20NE) (bioMérieux, Marcy l’Etoile, France). The bac-
teria were stored at −70°C in Protect® storage vials
(Key Scientific Products, Inc., Stamford, TX, USA). Fresh
isolates were sub-cultured twice on 5% blood agar plates
(Thermo Scientific Microbiology, Malaysia) for 24 hours
at 35°C prior to each experiment.
Genotypic identification
Clonal relatedness was determined by pulse-field gel
electrophoresis (PFGE). PFGE was performed on chro-
mosomal DNA extracts after digestion using ApaI [15].
Digital images of the DNA fingerprints were processed
using Molecular Analyst v1.6 (Bio-Rad, Hercules, CA,
USA) and analyzed using the Dice coefficient and the
unweighted-pair group method using average linkages.
Isolates with similarity coefficients greater than 90% were
considered to be within the same clonal cluster.
Resistance gene testing
Screening for the presence of genes encoding OXA-type
carbapenemases (blaOXA-23-like, blaOXA-24-like, blaOXA-58-
like, and blaOXA-51-like genes) and metallo-beta-lactamases
(MBL) (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM) was perfor-
med via multiplex polymerase chain reactions (PCR) using
protocols previously described in literature [16,17].
Minimum inhibitory concentration testing
Minimum inhibitory concentrations (MIC) to imipenem,
meropenem, doripenem, rifampicin, tigecycline and poly-
myxin B (PB) were obtained using broth dilution methodsin accordance to Clinical and Laboratory Standards (CLSI)
guidelines [18]. Categorical susceptibility was based on
CLSI guidelines except for rifampicin and tigecycline, for
which there are no standard breakpoints [19]. Breakpoints
for tigecycline susceptibility were interpreted according to
the US Food and Drug Administration standards for
Enterobacteriaceae spp.
Antimicrobial agents
Meropenem was obtained from AstraZeneca Inc. Imipe-
nem was obtained from Merck Sharp & Dohme (I.A.)
Corp. Doripenem was obtained from Johnson & Johnson
Pharmaceutical Research and Development. PB and rifam-
picin were obtained from Sigma-Aldrich (St Louis, MO,
USA). Tigecycline was obtained from Pfizer Inc.
Multiple combination bactericidal testing (MCBT)
MCBT was conducted with imipenem, meropenem, dor-
ipenem, rifampicin and tigecycline alone and in combin-
ation with PB. Clinically-relevant (achievable) unbound
concentrations of each antibiotic in blood or tissues
were used. Hence, the meropenem concentration was
64 mg/L, representing a steady-state free peak concen-
tration arising from a 2 g, 3-hour infusion dose [20].
Imipenem concentration was 32 mg/L, which simulates
the steady-state free peak concentration arising from a
1 g, 40-min infusion [21]. Doripenem concentration was
13 mg/L, which corresponds to the steady-state free
peak concentration arising from a 1 g, 4-hour infusion
[22]. The simulated steady-state drug concentrations were
2 mg/L (free or unbound protein fraction) for PB, rifampi-
cin and tigecycline, which corresponds to levels achieved
with maximum intravenous doses of at least 1 million
units of PB, 600 mg of rifampicin and 100 mg of tigecyc-
line respectively [23-25].
The experiment was conducted using 96-well, round-
bottom microtitre trays (Greiner Bio-One, Frickenhausen,
Germany). Working antibiotic solutions were prepared at
four times the required concentration. Each of one or two
antibiotics was added in 50 μL aliquots. Wells containing
only one antibiotic were topped up with 50 μL of sterile
water, such that all wells had a volume of 100 uL before
the addition of the bacterial suspension. Growth and
sterility wells were included in each tray. The trays were
then stored at −70°C and thawed before the start of each
experiment.
Overnight bacterial cultures were diluted with pre-
warmed cation-adjusted Mueller-Hinton broth (Ca-MHB)
(BBL, BD Diagnostic Systems, Sparks, MD, USA) and
incubated further at 35°C until log-phase growth was
reached. The bacterial inoculum was prepared by dilution
with Ca-MHB according to an ultraviolet spectrophotom-
etry calibration method (absorbance at 630 nm); 100 μL of
the suspension was transferred to each well, resulting in a
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and the desired concentration of antimicrobials in each
well. Each MCBT tray was then incubated in a humidified
incubator (35°C) for 24 hours.
The plates were examined for turbidity at 24 hours
and entire contents of each well (200 μL) were obtained
for quantitative culture. Samples were centrifuged at
10,000 × g for 15 minutes followed by decanting. The
pellets were then reconstituted with sterile normal saline
to their original volumes in order to minimize drug car-
ryover effect. Total bacterial populations were quantified
by spiral plating 10× serial dilutions of the samples
(50 μL) onto Mueller-Hinton agar plates. The plates
were incubated in a humidified incubator for up to
24 hours and the bacterial density from each sample was
enumerated visually. The theoretical reliable lower limit
of detection was 400 CFU/mL.
Bactericidal activity was defined as a ≥ 3 log10 CFU/mL
decrease in the colony count from the initial inoculum
at 24 hours, as the primary endpoint. This endpoint is
synonymous with sustained killing effect of ≥ 99.9% [26].
Emergence of resistance studies
To analyze the potential presence of PB heteroresistance,
24-hour PB time-kill studies were conducted as previously
described [9]. Briefly, colonies recovered at 24 hours in
the time-kill studies were cultured on Mueller-Hinton
agar supplemented with PB at 3 times the initial MIC of
PB. Repeat MIC testing was then performed on three
randomly chosen colonies recovered 24 hours post-PB ex-
posure on the PB-containing plates. Heteroresistance was
defined by growth of colonies on PB-containing plates,
with confirmation of an increased MIC of more than three
times the initial MIC upon repeat testing.
Results
Susceptibility studies
Forty-nine XDR AB isolates were identified. All isolates
were resistant to meropenem, imipenem, ampicillin/sul-
bactam, ciprofloxacin, gentamicin, aztreonam, piperacillin/
tazobactam, ceftazidime, cefepime and amikacin based
on susceptibility testing results from Thailand (data not
shown). They remained susceptible to PB (MIC range
0.5–2 mg/L). The MICs of rifampicin and tigecycline
ranged from 4–16 mg/L and 1–16 mg/L respectively
(Figure 1).
Clonal relationship analysis
The phylogenetic dendrogram of the XDR AB isolates is
shown in Figure 2. Eight clonal clusters containing 46
isolates were identified. The remaining three isolates
were clonally unrelated. Majority of the isolates (37/49,
75.5%) were retrieved from the medical units. Interest-
ingly, the five isolates in clonal cluster 3 were retrievedfrom the same surgical intensive care unit. During the
study period, real-time feedback of molecular epide-
miologic results was performed, followed by immediate
implementation of infection control measures, leading to
the reduction in transmission of XDR AB within the
institution [27,28].
Presence of resistance genes
blaOXA-51 gene, a naturally occurring resistance gene
unique to AB, was detected in all study isolates. In addition,
it was observed that all isolates were blaOXA-23 -harbouring,
a phenomenon reported to be highly-prevalent in Thailand
hospitals [29,30]. MBL genes were absent in our study
isolates.
MCBT studies
In single antibiotic MCBT, none of the antibiotics exhib-
ited bactericidal activity against all isolates at 24 hours ex-
cept for PB and tigecycline. Tigecycline was bactericidal
against 14 out of 49 isolates (28.6%) while PB was bacteri-
cidal against 43 out of 49 isolates (87.8%) (Table 1).
In combination MCBT, imipenem-PB, meropenem-PB
and rifampicin-PB combinations were bactericidal against
all 49 isolates, including the six isolates where PB alone
was not bactericidal. Doripenem-PB was not bactericidal
against only one isolate. Tigecycline-PB was only bacte-
ricidal against 87.8% of the isolates. Tigecycline MICs
of isolates where the tigecycline-PB combination failed
were ≥ 2 mg/L.
Emergence of resistance studies
PB alone was found to be rapidly bactericidal at 6 h
before regrowth occurred at 24 h with a final inoculum
of 3.40 to 6.50 log CFU/mL. Colonies were isolated on
PB-containing plates for four isolates. Repeat MIC test-
ing of three randomly chosen colonies from these four
isolates demonstrated a significant elevation in PB MIC
(256 mg/L). This suggests that PB heteroresistance may
be present in this group of XDR AB isolates.
Discussion
There were some key findings in this study. Firstly,
nearly all XDR AB isolates were clonally related and had
the same resistance gene profile. Secondly, our results
showed that PB in combination with either imipenem,
meropenem or rifampicin was consistently bactericidal
for all of our XDR AB isolates. The high clonal related-
ness suggests that creation of unit-specific antibiograms
and combination antibiograms based on our findings
may have a potential role in the guidance of appropriate
empirical combination therapy.
Our study suggested the feasibility of using molecular
epidemiologic analysis to limit the transmission of XDR
AB in a resource-limited setting in Thailand. At the
Figure 1 Phylogenetic tree diagram. A blue oval shape denotes a clonal group after applying a similarity index of≥ 90%.
Teo et al. Antimicrobial Resistance and Infection Control  (2015) 4:2 Page 4 of 7beginning of our study (October 2010), the hospital saw
an increase in the incidence of XDR AB. Molecular ana-
lysis (including resistance gene testing), which was con-
tinued throughout our study period, identified that the
isolates were clonally related. This information was piv-
otal in identifying the outbreak. At the time of the study,
standard infection control measures such as hand hy-
giene and contact isolation precautions, as well as anantimicrobial stewardship programme were already
present. In response to the molecular results, new mea-
sures including environmental cleaning, active surveil-
lance in index units and cohorting were promptly
introduced by December 2010. Advanced source control
(chlorhexidine bath and oral care) was also implemented
in intensive care units. In addition, staff education pro-
grammes were organised and adherence monitoring with
Figure 2 Susceptibilities of XDR AB to carbapenems (A), polymyxin B (B), rifampicin (C) and tigecycline (D).
Teo et al. Antimicrobial Resistance and Infection Control  (2015) 4:2 Page 5 of 7unit-specific feedback was introduced. Following the
implementation, incidence of XDR AB slowly decreased
[27,28]. Although molecular epidemiologic analysis was
not continued after the study period, data from our
study highlight the utility of such a strategy in outbreak
control.
We noted that blaOXA-23 was a major resistance deter-
minant in our study. This observation concurred with
studies in the Southeast Asian and Asian region. blaOXA-23
genes were detected in most of the carbapenemase-
producing AB (91%) in a Singapore hospital, while blaIMP-4
and blaOXA-58 genes were also detected in a few isolatesTable 1 Bactericidal activity of single antibiotics and
combination antibiotics against XDR AB












Tigecycline-PB 87.8[15]. blaOXA-23 is also highly prevalent in countries such as
China and Korea, where 40 – 100% of the carbapenem-
resistant AB isolates were found to carry the gene [31,32].
In our study, we also observed that antimicrobial
monotherapies had little or no bactericidal activity, with
the exception of PB which retained bactericidal activity
in the majority of the isolates. However, when PB mono-
therapy is employed, there is the possibility of the emer-
gence of heteroresistant populations [6]. The inability of
PB monotherapy to be universally bactericidal, despite
all isolates having MICs ≤ 2 mg/L, suggested the pres-
ence of such heteroresistant populations in our isolates.
Indeed, further testing proved that a number of isolates
exhibited increased MIC post-PB exposure in our study.
This underscores the need for combination therapies to
reduce the chance of clinical failure. The high in vitro
bactericidal activity (near 100% of all combinations ex-
cept tigecycline-PB) of the combinations suggested that
combination therapy may overcome the selection of PB-
heteroresistant populations associated with PB mono-
therapy. Hence, one potential interesting approach to
aid the reduction of antibiotic resistance is to use unit-
specific combination antibiograms to help guide empir-
ical therapy. The use of combination antibiograms had
been shown to help clinicians provide early appropriate
antimicrobial therapy in an XDR AB endemic setting
[33]. In vitro and animal studies have suggested promising
synergism/bactericidal activity of antibiotic combinations
against highly-resistant AB [8-10,34]. A recent systematic
review has also elucidated that carbapenem-polymyxin
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synergism, low antagonism and reduced development of
resistance especially for resistant AB infections [35]. Like-
wise, we demonstrated that combination therapy, PB in
combination with an anti-pseudomonal carbapenem or ri-
fampicin in our case, exhibited bactericidal activity in vitro
against XDR AB.
The utility of combination therapy has also been evalu-
ated in the clinical setting. Whilst the limited randomized
controlled trials available were unable to conclusively
demonstrate the clinical benefit of combination therapy in
the clinical setting [36,37], results from observational
studies have suggested that combination therapy may be
beneficial for the treatment of carbapenem-resistant AB in
Thailand [38,39] and elsewhere [40].
We had elected to perform our in vitro tests using
MCBT [41,42]. While MCBT has not been used in the
region, variations of this testing method have been
adopted elsewhere to investigate combination therapies
[43,44]. Our method allowed the efficient measurement
of bactericidal activity of multiple different combinations
against XDR AB at any one time in a 96-well plate.
Furthermore, maximal clinically-achievable unbound
concentrations of antibiotics were employed to mimic
the in vivo killing effect when maximum antibiotic
doses were used, allowing better clinical extrapolation
of the results.
Our study is limited by the nature of study isolates from
a single institution and the assessment of PB-susceptible
strains which may not allow the generalizability of our
results. In addition, in vitro synergism and/or bactericidal
activity are highly dependent on the test methods, of
which currently has not been standardized. It is unknown
which method best predicts in vivo efficacy. It appears that
our test method overestimates the bactericidal activity of
polymyxin monotherapy. The heteroresistance phenome-
non was not detected in our MCBT experiments. One of
the reasons could be due to the small test volumes utilized
in our experiments, and the corresponding likelihood that
the percentage of hetero-resistant sub-population is very
minute. As a result, it is difficult to elucidate such strains
through small quantitative cultures. Furthermore, until re-
sources are readily available, we are unable to implement
MCBTas a routine test in our clinical setting.
Conclusions
The lack of therapeutic options in the treatment of XDR
AB infections and risk of clinical failure associated with
polymyxin monotherapy highlighted the need to identify
effective combination therapies. The clinical relevance of
molecular epidemiology in the containment of XDR AB
infections together with the effectiveness of combination
therapy should be further studied in a resource-limited
setting.Abbreviations
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